TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy com
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-03-30 7:00 AM EDT | TempraMed Technologies Ltd.
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executi
Biotechnologies, Pharmaceutique, Santé
2026-03-30 3:00 AM EDT | PreveCeutical Medical Inc.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's
Biotechnologies, Pharmaceutique
2026-03-27 5:05 PM EDT | InMed Pharmaceuticals
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development. The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic c
2026-03-27 8:00 AM EDT | Shuttle Pharmaceuticals Holdings Inc.
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development. The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic c
2026-03-26 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced i
Biotechnologies, Pharmaceutique
2026-03-26 8:00 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*. VINIA's leadership position is driven by its clinically demonstrate
Biotechnologies, Pharmaceutique, Santé
2026-03-26 7:30 AM EDT | BioHarvest Sciences Inc.
NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology
Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering a Ready-to-Fill (RTF) COP/COC injection nozzle designed specifically for pharmaceutical needle-free applications. The nozzle, which is the subject of a newly filed patent application, represents a novel pharmaceutical packaging component that enables needle-free injection using established ase
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-25 5:15 PM EDT | NuGen Medical Devices Inc.
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases. Key fourth-quarter, full-year 2025, and recent corporate highlights include: Advanced KIO-301 from regulatory clearance to patient
Biotechnologies, Pharmaceutique
2026-03-25 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box
Highlights Chinese patent officially granted by CNIPA on March 17, 2026 Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026 Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engag
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-03-24 7:00 AM EDT | TempraMed Technologies Ltd.
Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries. The Company is pleased to announce that Dr. Joel M. Hawkins has expanded his consulting role with Telescope. Dr. Hawkins is an industry-wide authority in automating complex chemistry workflows
Technologies, Produits chimiques, Pharmaceutique
2026-03-23 8:00 AM EDT | Telescope Innovations Corp.
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of di
Biotechnologies, Pharmaceutique
2026-03-23 7:30 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Col
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
Defence Therapeutics Announces Warrant Terms Amendment
Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and th
Biotechnologies, Pharmaceutique, Santé
2026-03-20 6:00 PM EDT | Defence Therapeutics Inc.
Healthcare Technology Research Company, KLAS Research, Reports 100% of Surveyed Customers Would Buy Vectramind Health's Firstpass Platform Again
Dubai, United Arab Emirates--(Newsfile Corp. - March 17, 2026) - Vectramind Health today announced that its AI-native patient experience and engagement platform, Firstpass, has received strong validation in a newly released KLAS First Look report highlighting high levels of customer satisfaction and measurable improvements in patient engagement and operational efficiency. The findings, published in the KLAS Research report 'Vect
Technologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-17 10:06 AM EDT | Vectramind Health
BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the re
Biotechnologies, Pharmaceutique, Santé
2026-03-17 8:30 AM EDT | BioHarvest Sciences Inc.
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action ("MOA") as to how Ruvidar® is
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-17 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silenc
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-16 11:30 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations and AGI SDA Launch Technology Development Collaboration
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a developer of enabling technologies and services for the global pharmaceutical and high value chemical industries, with established leadership in sampling systems for monitoring chemical and biological processes. The Company is pleased to announce that it has signed a Development and Collaboration Agreemen
Technologies, Produits chimiques, Pharmaceutique
2026-03-16 8:00 AM EDT | Telescope Innovations Corp.